Author

Ivan Marquez-Rodas

Instituto de Investigaci

Biography

Dr. Ivan Marquez-Rodas is currently working at Oncologia Medical Department. Ivan Marquez-Rodas is research interests includes Oncologia Medical in Cancer. Ivan Marquez-Rodas serving as an editorial member and reviewer of several international reputed journals. Ivan Marquez-Rodas has successfully completed his Administrative responsibilities. Ivan Marquez-Rodas has authored of many research articles/books related to Medicine.
Title
Cited by
Year
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled …
PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ...The Lancet Oncology 21 (11), 1465-1477, 2020202
350
2020
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...Journal of Clinical Oncology 40 (2), 127-137, 2022202
297
2022
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...Journal of Clinical Oncology 39 (15_suppl), 9506-9506, 2021202
99
2021
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
FS Hodi, V Chiarion-Sileni, KD Lewis, JJ Grob, P Rutkowski, CD Lao, ...Journal of Clinical Oncology 40 (16_suppl), 9522-9522, 2022202
32
2022
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.
AM Arance, L de la Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ...Journal of Clinical Oncology 39 (15_suppl), 9504-9504, 2021202
29
2021
SEOM clinical guideline for the management of cutaneous melanoma (2020)
M Majem, JL Manzano, I Marquez-Rodas, K Mujika, E Muñoz-Couselo, ...Clinical and Translational Oncology 23, 948-960, 2021202
26
2021
Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor …
A Arance, L De La Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ...Journal of Clinical Oncology 41 (1), 75-85, 2023202
25
2023
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511.
C Lebbe, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ...Journal of Clinical Oncology 39 (15_suppl), 95-95, 2021202
16
2021
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
J Larkin, J Weber, M Del Vecchio, H Gogas, AM Arance, S Dalle, ...European Journal of Cancer 173, 285-296, 2022202
13
2022
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
M Gonzalez-Cao, T Puertolas, M Riveiro, E Muñoz-Couselo, C Ortiz, ...Journal for ImmunoTherapy of Cancer 9 (3), 2021202
13
2021
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
M Martin, R Ramos-Medina, R Bernat, JA García-Saenz, ...Scientific Reports 11 (1), 7064, 2021202
12
2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
M Mandala, J Larkin, PA Ascierto, M Del Vecchio, H Gogas, CL Cowey, ...Journal for immunotherapy of cancer 9 (8), 2021202
7
2021
1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the …
I Marquez-Rodas, A Arance, MAB Guerrero, RD Beveridge, MDC Alamo, ...Annals of Oncology 32, S870, 2021202
6
2021
961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti …
IM Rodas, P Saiag, L de la Cruz Merino, C Dutriaux, J Rodríguez-Moreno, ...Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021202
5
2021
CCL20/TNF/VEGFA cytokine secretory phenotype of tumor-associated macrophages is a negative prognostic factor in cutaneous melanoma
A Gutiérrez-Seijo, E García-Martínez, C Barrio-Alonso, M Pareja-Malagón, ...Cancers 13 (16), 3943, 2021202
5
2021
COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study
M Gonzalez-Cao, C Carrera, JFR Moreno, P Rodríguez-Jiménez, ...Journal of the American Academy of Dermatology 8 (5), 112-115, 2021202
4
2021
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
SK Wong, SM Blum, X Sun, IP Da Silva, L Zubiri, F Ye, K Bai, K Zhang, ...European Journal of Cancer 181, 188-197, 2023202
4
2023
EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.
M Weichenthal, IM Svane, L Kandolf Sekulovic, J Mangana, P Mohr, ...Journal of Clinical Oncology 0 (16_suppl), 950-950, 2022202
4
2022
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
J Larkin, M Del Vecchio, M Mandala, H Gogas, AM Arance Fernandez, ...Clinical cancer research, OF1-OF10, 2023202
4
2023
Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have …
Abstract CT2: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have …I Márquez-Rodas, M Fernández de Sanmamed Gutiérrez, MG Cao, ...Cancer Research 81 (1_Supplement), CT2-CT2, 2021202
3
2021

Referred From: https://scholar.google.se/citations?user=Mf85-XsAAAAJ&hl=th

Cited by
Citations 21854
h-index 36
i10-index 84
Recommended Journals
Open Access Journals